Cargando…
β-Sheet Breaker Peptide-HPYD for the Treatment of Alzheimer's Disease: Primary Studies on Behavioral Test and Transcriptional Profiling
Background: Alzheimer's disease (AD), is a progressive neurodegenerative disease that is characterized by cognitive loss. Most researchers believe that aggregation and accumulation of β-amyloid peptides (Aβ) in brain cells are the central pathological hallmark of this disease. Methods: Based on...
Autores principales: | Liu, Weiying, Sun, Fengxian, Wan, Moxin, Jiang, Fang, Bo, Xiangyu, Lin, Laixiang, Tang, Hua, Xu, Shumei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5766670/ https://www.ncbi.nlm.nih.gov/pubmed/29358920 http://dx.doi.org/10.3389/fphar.2017.00969 |
Ejemplares similares
-
Feasibility of β-Sheet Breaker Peptide-H102 Treatment for Alzheimer's Disease Based on β-Amyloid Hypothesis
por: Lin, Lai-xiang, et al.
Publicado: (2014) -
Nanomedicine against Aβ Aggregation by β–Sheet Breaker Peptide Delivery: In Vitro Evidence
por: Pederzoli, Francesca, et al.
Publicado: (2019) -
Consecutive Aromatic Residues Are Required for Improved Efficacy of β-Sheet Breakers
por: Jarmuła, Adam, et al.
Publicado: (2022) -
Preventing β-amyloid fibrillization and deposition: β-sheet breakers and pathological chaperone inhibitors
por: Wisniewski, Thomas, et al.
Publicado: (2008) -
Destabilization potential of beta sheet breaker peptides on Abeta fibril structure: an insight from molecular dynamics simulation study
por: Jani, Vinod, et al.
Publicado: (2021)